BioNTech SE/BNTX

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About BioNTech SE

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Ticker

BNTX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

Headquarters

Mainz, Germany

Employees

6,133
Website
www.biontech.com

BioNTech SE Metrics

BasicAdvanced
$24B
Market cap
195.10
P/E ratio
$0.52
EPS
0.26
Beta
-
Dividend rate
$24B
0.26
$125.83
$85.21
15
11.379
11.164
1.027
1.183
0.51%
0.56%
0.55%
195.096
8.082
1.105
1.175
4.462
-77.65%
-98.08%
99.31%
299.76%

What the Analysts think about BioNTech SE

Analyst Ratings

Majority rating from 19 analysts.
Hold

BioNTech SE Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-167.96% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
€188M
-87.32%
Net income
-€315M
-168.81%
Profit margin
-167.96%
-642.51%

BioNTech SE Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 20.64%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-€0.79
€0.67
€1.90
-€1.31
-
Expected
-€0.96
-€0.10
€2.42
-€1.09
-€2.03
Surprise
-17.61%
-796.10%
-21.50%
20.64%
-

BioNTech SE News

AllArticlesVideos

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union

GlobeNewsWire·6 days ago

BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer

GlobeNewsWire·1 week ago

Why Is Pfizer Partner BioNTech Stock Trading Lower On Monday?

Benzinga·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market openNon-fractionalADR

Upcoming events

No upcoming events

FAQs

What’s the current market cap for BioNTech SE stock?

BioNTech SE (BNTX) has a market cap of $24B as of July 03, 2024.

What is the P/E ratio for BioNTech SE stock?

The price to earnings (P/E) ratio for BioNTech SE (BNTX) stock is 195.1 as of July 03, 2024.

Does BioNTech SE stock pay dividends?

No, BioNTech SE (BNTX) stock does not pay dividends to its shareholders as of July 03, 2024.

When is the next BioNTech SE dividend payment date?

BioNTech SE (BNTX) stock does not pay dividends to its shareholders.

What is the beta indicator for BioNTech SE?

BioNTech SE (BNTX) has a beta rating of 0.26. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell BioNTech SE stock

Buy or sell BioNTech SE stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing